These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2736490)

  • 1. Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells.
    Nio Y; Zighelboim J; Berek J; Bonavida B
    Cancer; 1989 Jul; 64(2):434-41. PubMed ID: 2736490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Cancer Immunol Immunother; 1988; 27(3):246-54. PubMed ID: 3180149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of human peripheral blood-derived monocytes by OK-432 (Streptococcus pyogenes): augmented cytotoxicity and secretion of TNF and synergy with rIFN-gamma.
    Bonavida B; Jewett A
    Cell Immunol; 1989 Oct; 123(2):373-83. PubMed ID: 2507170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to autologous peripheral blood lymphocytes.
    Mizutani Y; Nio Y; Yoshida O
    Cancer; 1992 Jun; 69(12):2999-3007. PubMed ID: 1591693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). II. Analysis of the cytotoxic lymphocytes induced by OK-432 injection into tumor-bearing F344 rats.
    Fukui H; Reynolds CW
    J Natl Cancer Inst; 1987 Nov; 79(5):1019-24. PubMed ID: 3500354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432, a streptococcal preparation.
    Katano M; Yamamoto H; Mizoguchi T; Hisatsugu T
    Cancer Immunol Immunother; 1988; 27(3):198-204. PubMed ID: 3141056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of cytotoxic factor into mouse peritoneal fluid by OK-432, a streptococcal preparation.
    Yamamoto A; Nagamuta M; Usami H; Sugawara Y; Watanabe N; Niitsu Y; Urushizaki I
    Immunol Lett; 1985; 11(2):83-8. PubMed ID: 4086064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced antitumor and immune-adjuvant activities of the sub-cellular fractions from Group A Streptococcus.
    Ryoyama K; Natsuume-Sakai S; Hirota H; Koshimura S
    Jpn J Exp Med; 1981 Dec; 51(6):335-44. PubMed ID: 7040746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative experiments with hemolytic streptococcus and its anticancer preparations (OK-431 and OK-432) for their cytolytic activity.
    Higuchi Y; Kigoshi S; Shoin S
    Jpn J Exp Med; 1980 Feb; 50(1):7-12. PubMed ID: 7382135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of tumor necrosis factor by administration of OK-432 in cancer patients.
    Kokunai I; Shimano T; Sekimoto K; Takeda T; Kobayashi T; Yayoi E; Yamamoto A; Mori T
    J Clin Lab Immunol; 1986 Dec; 21(4):169-71. PubMed ID: 3560194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Augmentation of the cytostatic activity of granulocytes by biological response modifiers (BRM)].
    Shimizu E; Saijo N; Shibuya M; Takizawa T; Fujioka Y; Hoshi A
    Gan To Kagaku Ryoho; 1983 Sep; 10(9):2030-5. PubMed ID: 6577815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). I. Sequential effector mechanisms following a single OK-432 injection in F344 rats leading to the rejection of syngeneic MADB106 tumor cells.
    Fukui H; Reynolds CW
    J Natl Cancer Inst; 1987 Nov; 79(5):1011-7. PubMed ID: 3479632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Production of a cytotoxic factor in mouse peritoneal fluid by OK-432, a streptococcal preparation].
    Yamamoto A; Nagamuta M; Usami H; Sugawara Y; Watanabe N; Niitsu Y; Urushizaki I
    Gan To Kagaku Ryoho; 1986 May; 13(5):1905-10. PubMed ID: 3707150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of OK-432 (picibanil) on the estrogen receptors of MCF-7 cells and potentiation of antiproliferative effects of tamoxifen in combination with OK-432.
    Aoyagi H; Iino Y; Takeo T; Horii Y; Morishita Y; Horiuchi R
    Oncology; 1997; 54(5):414-23. PubMed ID: 9260604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of endogenous cytokines in ascites of patients with ovarian cancer by OK-432, a streptococcal preparation.
    Mori H; Itoh N; Yamada Y; Tamaya T
    Asia Oceania J Obstet Gynaecol; 1989 Sep; 15(3):281-9. PubMed ID: 2512905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.
    Wakasugi H; Oshimi K; Miyata M; Morioka Y
    J Clin Immunol; 1981 Jul; 1(3):154-62. PubMed ID: 6174541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic actions of picibanil (OK-432) on recombinant interleukin-2 induction of tumor-infiltrating lymphocyte expansion, cytotoxicity, and phenotypic differentiation.
    Lafreniere R; Borkenhagen K; Bryant LD; Ng E; Hayton S
    J Biol Response Mod; 1990 Feb; 9(1):53-60. PubMed ID: 2181072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of tumor necrosis factor (TNF) by monocytes from cancer patients and healthy subjects induced by OK-432 in vitro, and its augmentation by human interferon gamma.
    Sekimoto M; Kokunai I; Shimano T; Kobayashi T; Takeda T; Haruna N; Yamamoto A; Mori T
    J Clin Lab Immunol; 1988 Nov; 27(3):115-20. PubMed ID: 3150012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.